Dr. Howard Hochster is a Professor of Medicine at Yale School of Medicine (Medical Oncology), the Associate Cancer Center Director for Clinical Research at Yale Cancer Center and the Director of the GI Oncology Program. Click here for Dr. Hochster’s bio.
Each year in the United States, more than 100,000 people are diagnosed with colon cancer. Advances in early detection and treatment have made important contributions to improved survival, but researchers continue to explore more targeted and more individualized approaches to cancer care.
As cancer research has evolved, it has become apparent that no two cancers are exactly alike. Even among people with the same type and stage of cancer, the specific characteristics of the cancer can vary greatly. These differences can have a profound effect on prognosis and response to treatment. The good news is that a growing collection of tests are available to describe the important characteristics of a tumor and guide treatment choices.
On Tuesday, November 8, 2011 at 6:00 PM you’ll have the opportunity to ask the expert, Dr. Howard S. Hochster, about the range of treatment options available for early-stage colon cancer. Dr. Hochster is a world-renowned authority in this area. He has published widely on treatment of colon, pancreatic, and gastric cancer, and has been in the forefront of developing newer chemotherapy and targeted agents for these diseases.
The Web Chat is in two parts: the live Q&A will follow Dr. Hochster’s presentation. Click here to submit a question to Dr. Hochster that will be answered during the Live Web Chat. Please note, we will do our best to respond to all questions during the 30-minute live Q&A portion of the program. Thank you for your participation.
This program is sponsored by Genomic Health, Inc. Please visit Oncotype DX to learn more.
Copyright © 2018 CancerConnect. All Rights Reserved.